The expression of CCAT1, an lncRNA transcribed from a distinct c-MYC SE in CIMP + colon cancers, predicted JQ1 sensitivity and BET-mediated c-MYC transcription, suggesting it as a clinically tractable biomarker for identifying patients who will likely benefit from BET inhibitors [100]. The gene discussed is MYC; the disease is malignant colon neoplasm.